Edwards Lifesciences
EW
$89.79
-0.04%
Edwards Lifesciences is a global leader in structural heart disease medical devices, specializing in surgical tissue heart valves, transcatheter aortic valve replacement (TAVR), and transcatheter mitral and tricuspid therapies. The company holds a dominant market position in TAVR, with a strong pipeline and a reputation for innovation in minimally invasive heart valve technologies. Currently, the stock is in focus due to a proposed expansion of Medicare coverage for TAVR procedures, which could significantly broaden patient access and drive growth, alongside a recent beat-and-raise quarter that highlighted robust demand for its heart valve therapies.…
EW
Edwards Lifesciences
$89.79
Related headlines
Investment Opinion: Should I buy EW Today?
Based on the analysis, EW is rated a Buy. The company has strong fundamentals, including accelerating revenue growth of 16.7% YoY, high gross margins of 78.2%, and a robust balance sheet. The consensus analyst target of $100.96 implies a 10.2% upside, and the recent positive catalysts, such as the Medicare expansion proposal, support a bullish outlook. The stock is suitable for investors seeking growth in the medical device sector, with a long-term horizon.
Sign up to view all
EW 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The company's strong fundamentals, including accelerating revenue growth and high margins, support a positive outlook. The potential Medicare expansion is a significant catalyst that could drive growth. However, the premium valuation and negative PEG ratio introduce uncertainty. The stance would be upgraded to high confidence if revenue growth exceeds 20% and the Medicare expansion is confirmed. It would be downgraded to neutral if growth decelerates below 10% or if the stock's P/E exceeds 50x without corresponding growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Edwards Lifesciences's 12-month outlook, with a consensus price target around $100.96 and implied upside of +12.4% versus the current price.
Average Target
$100.96
0 analysts
Implied Upside
+12.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $110
Analyst target range
Edwards Lifesciences is covered by 26 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.64 (where 1 is Strong Buy and 5 is Sell). The average price target is $100.96, implying an upside of 10.2% from the current price of $91.60. The target range is $84.00 to $110.00, with the low target suggesting a potential downside of 8.3% and the high target implying a 20.1% upside. The wide spread of $26 indicates moderate uncertainty, but the recent ratings from firms like Mizuho, RBC Capital, and Citigroup are all positive, with no downgrades in the last three months, signaling a bullish sentiment among analysts.
Bulls vs Bears: EW Investment Factors
Edwards Lifesciences presents a compelling growth story with accelerating revenue, high margins, and a potential Medicare catalyst. However, the stock trades at a significant premium to peers, and the negative PEG ratio raises concerns about valuation sustainability. The bull case is supported by strong fundamentals and analyst optimism, but the bear case highlights the risk of multiple compression if growth slows. The key tension is whether the company can deliver the high growth implied by its valuation, particularly in the face of competitive and regulatory risks. Currently, the evidence slightly favors the bulls given the strong quarter and positive catalyst, but investors should monitor valuation and growth trajectory closely.
Bullish
- Strong Revenue Acceleration: Q1 2026 revenue grew 16.7% YoY to $1.65B, accelerating from 10.9% in Q1 2025, driven by robust demand for TAVR and TMTT therapies. This momentum suggests the company is gaining market share and benefiting from expanded indications.
- High Gross Margin and Profitability: Gross margin is 78.2%, reflecting strong pricing power and efficient manufacturing. Operating margin is 27.0%, and net margin is 23.1%, demonstrating the company's ability to convert revenue into profit at scale.
- Potential Medicare Expansion Catalyst: A proposed expansion of Medicare coverage for TAVR could significantly broaden patient access, driving volume growth. As the market leader, Edwards is well-positioned to capture this incremental demand, potentially accelerating revenue growth beyond current estimates.
- Robust Balance Sheet and FCF: Debt-to-equity is only 0.068, and the company generated $1.09B in free cash flow over the TTM, providing ample liquidity for R&D, M&A, and shareholder returns. This financial strength supports continued investment in innovation.
Bearish
- Premium Valuation vs. Peers: Trailing P/E is 46.3x, a 111% premium to the industry average of 22x. Even forward P/E of 27.1x is above the sector, implying high growth expectations that may already be priced in, leaving limited room for error.
- Negative PEG Ratio Signals Risk: The PEG ratio is -0.63, indicating that expected earnings growth may not justify the current valuation, or that growth is expected to decelerate. This could lead to multiple compression if growth disappoints.
- Underperformance vs. S&P 500: Over the past year, EW returned 17.2% vs. the S&P 500's 20.4%, and relative strength is -3.2%. This suggests the stock has lagged the broader market, potentially due to sector rotation or specific concerns.
- Dependence on TAVR Market: The Transcatheter Heart Valves segment accounts for ~73% of revenue, creating concentration risk. Any competitive threat or regulatory setback in TAVR could significantly impact the company's financials.
EW Technical Analysis
Edwards Lifesciences is in a clear uptrend, with the stock up 17.17% over the past year, currently trading at $91.60, which is 95.1% of its 52-week range (low $72.30, high $96.29). This positioning near the highs indicates strong momentum, though it also suggests the stock may be somewhat overextended in the short term. The 1-year price change of 17.17% outpaces the S&P 500's 20.37% gain, but the relative strength over 1 year is negative at -3.20%, indicating the stock has underperformed the broader market over that period.
Beta
0.85
0.85x market volatility
Max Drawdown
-13.2%
Largest decline past year
52-Week Range
$72-$96
Price range past year
Annual Return
+10.6%
Cumulative gain past year
| Period | EW Return | S&P 500 |
|---|---|---|
| 1m | +6.4% | +2.5% |
| 3m | +4.7% | +2.7% |
| 6m | +12.5% | +11.1% |
| 1y | +10.6% | +20.5% |
| ytd | +5.2% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EW Fundamental Analysis
Edwards Lifesciences reported Q1 2026 revenue of $1.6486 billion, a 16.7% year-over-year increase, accelerating from the 10.9% growth seen in Q1 2025. This growth is driven by strong demand for its Transcatheter Heart Valves segment, which generated $1.1973 billion in revenue, and the Transcatheter Mitral and Tricuspid Therapies segment contributing $175.1 million. The company's net income for Q1 2026 was $380.7 million, with a net margin of 23.1%, up from 25.3% in the prior year quarter, indicating expanding profitability. Gross margin remained high at 78.2%, reflecting the company's pricing power and efficient manufacturing. The balance sheet is robust with a debt-to-equity ratio of just 0.068, and the company generated $1.0895 billion in free cash flow over the trailing twelve months, providing ample liquidity for internal funding and strategic investments.
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+16.7%
YoY Comparison
Gross Margin
78.2%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EW Overvalued?
Given Edwards Lifesciences' positive net income, the trailing P/E ratio of 46.33x is the primary valuation metric, with a forward P/E of 27.14x, implying the market expects significant earnings growth. The stock trades at a premium to the industry average P/E of 22x, a 111% premium, reflecting its market leadership and growth prospects. However, the PEG ratio is negative at -0.63, indicating that the earnings growth rate is expected to be high, but the negative value suggests a potential earnings decline or unusual accounting items. Historically, the stock's P/E has ranged from 28x to 60x over the past five years, and the current 46x is near the middle of that range, suggesting the valuation is not at extreme levels but still reflects optimism about future growth.
PE
46.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 27x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks include the company's high valuation, which leaves little room for error. The trailing P/E of 46.3x is well above the industry average of 22x, and the negative PEG ratio suggests that earnings growth may not justify the premium. Additionally, the company's revenue is heavily concentrated in the TAVR segment (73% of revenue), making it vulnerable to any disruption in that market. While the balance sheet is strong with a debt-to-equity of 0.068, the company's reliance on continued growth to sustain its valuation is a key risk. If revenue growth decelerates from the current 16.7% YoY, the stock could face significant de-rating.